Abstract | Genome-wide molecular-profiling studies have revealed the characteristic genetic alterations and epigenetic profiles associated with different types of gliomas. These molecular characteristics can be used to refine glioma classification, to improve prediction of patient outcomes, and to guide individualized treatment. Thus, the WHO Classification of Tumours of the Central Nervous System was revised in 2016 to incorporate molecular biomarkerstogether with classic histological features -in an integrated diagnosis, in order to define distinct glioma entities as precisely as possible. This paradigm shift is markedly changing how glioma is diagnosed, and has important implications for future clinical trials and patient management in daily practice. Herein, we highlight the developments in our understanding of the molecular genetics of gliomas, and review the current landscape of clinically relevant molecular biomarkers for use in classification of the disease subtypes. Novel approaches to the genetic characterization of gliomas based on large-scale DNA-methylation profiling and next-generation sequencing are also discussed. In addition, we illustrate how advances in the molecular genetics of gliomas can promote the development and clinical translation of novel pathogenesis-based therapeutic approaches, thereby paving the way towards precision medicine in neuro-oncology.
1
. Gliomas are the most common primary CNS tumours, with an estimated annual incidence of 6.6 per 100,000 individuals in the USA 2 . About half of all newly diagnosed gliomas are classified as glioblastoma, which is the most malignant type of brain cancer -with median patient survival durations of approximately 14-17 months in contemporary clinical trials [3] [4] [5] and ~12 months in population-based studies 2, 6 . Studies in transgenic mice indicate that gliomas can arise from a range of cell types, including neural stem cells, astrocytes, or oligodendroglial progenitor cells 7 . In addition, genome-wide molecular-profiling studies have revealed comprehensive mutational landscapes for all major types of human gliomas occurring in adults [8] [9] [10] [11] [12] and in children [13] [14] [15] [16] [17] [18] [19] [20] [21] . These developments have markedly advanced our mechanistic understanding of glioma tumorigenesis, and have identified novel biomarkers for improved tumour classification, as well as promising new therapeutic targets.
Before publication of the revised WHO Classification of Tumours of the CNS in 2016 (REF. 22 ), gliomas were exclusively classified following examination of tumour specimens using light microscopy, according to histological criteria defined in the 2007 WHO classification 23 . In addition to histological tumour typing, each tumour is assigned a histological grade based on the degree of anaplasia, from WHO grade I to IV. This WHO grading system reflects the degree of tumour malignancy and presumed natural disease course, with WHO grade I indicating a slow-growing lesion usually associated with a favourable prognosis, whereas WHO grade IV is assigned to highly malignant tumours. Histological classification has for many decades served as the 'gold standard' for glioma diagnostics, but is associated with considerable interobserver variability, particularly in the context of diffusely infiltrating gliomas 24 . Data from various studies have revealed that molecular classification of gliomas better correlates with clinical outcome than histological classification 10, 11, 25, 26 . Moreover, certain histo logical entities, such as glioblastoma, encompass a spectrum of biologically distinct tumour groups associated with differences in age at onset, tumour location, and prognosis 8, 9, 12, 21 . In addition, some traditional glioma categories, including oligoastrocytoma and glioma tosis cerebri, lack disease-specific genetic profiles, and consist of diverse astrocytic and oligodendroglial entities 27, 28 . In the revised 2016 WHO Classification of Tumours of the CNS 22 , the advances in our molecular understanding of gliomas are leveraged in a novel, multilayered approach to disease categorization that incorporates both histological and molecular information in an ' integrated diagnosis' 29, 30 . In this Review, we highlight advances in the molecular genetics of gliomas, with a particular focus on diagnostically relevant alterations. In addition, we address the role of predictive biomarkers and novel high-throughput molecular testing in glioma diagnostics, and discuss the implications of these advances for the clinical management of patients with glioma, as well as the design of future clinical trials.
Molecular genetics of adult gliomas
A major improvement in the 2016 WHO classification of gliomas, compared with the preceding 2007 classification, is the distinction of different glioma entities according to isocitrate dehydrogenase 1 or 2 (IDH)-mutation status (TABLE 1) . The discovery of IDH mutations in most WHO grade II and III gliomas constituted a key breakthrough in the understanding of this disease [31] [32] [33] . Data from numerous studies have revealed that the presence of IDH mutations distinguishes gliomas with distinct biologies and clinical behaviours 34 . Mechanistically, mutant IDH proteins acquire a neomorphic enzymatic activity that results in conversion of α-ketoglutarate (α-KG) to d-2-hydroxyglutarate (d-2-HG), which in turn inhibits α-KG-dependent dioxygenases, such as ten-eleven translocation (TET) family 5-methylcytosine hydroxylases and the Jumonji-C-domain-containing histone-lysine demethylases 35 . As a consequence, IDH mutation causes aberrant DNA and histone methylation, eventually leading to widespread hypermethylation of CpG islands, a phenomenon termed the 'glioma CpG-island methylator phenotype' (G-CIMP) 36 . Diagnostic testing for IDH mutations usually involves immuno staining with an antibody to IDH1-R132H protein 37 , which enables detection of the most-common missense mutation in gliomas (present in approximately 90% of the IDH-mutated tumours), and has proved reliable across different laboratories 38 . Immunonegative tumours, however, require additional molecular testing -for example, by DNA sequencing -to rule out the presence of other IDH1 or IDH2 mutations 22, 30 . In the following sections, we briefly summarize the genetic alterations most commonly associ ated with the prototypic glioma entities defined in the 2016 WHO classification (TABLE 1) .
Diffuse gliomas
The diffuse astrocytic and oligodendroglial tumour category of brain cancers comprises several diverse glioma subtypes. IDH-mutant astrocytic gliomas of WHO grades II-IV, IDH-mutant and 1p/19q-codeleted oligodendroglial tumours of WHO grades II-III, IDH-wild-type glioblastomas of WHO grade IV, and a newly introduced class of histone H3-K27M (H3-K27M)-mutant diffuse midline gliomas of WHO grade IV are the main disease entities included in this group 22 (TABLE 2; FIG. 1) . IDH-wild-type diffuse and anaplastic astrocytomas (WHO grades II and III, respectively) are considered provisional categories in the 2016 WHO classification (TABLE 2) . In adults, most of these tumours are associated with a poor prognosis and often harbour genetic aberrations that are detected in patients with IDH-wild-type glioblastomas, indicating that such cases might reflect underestimation of malignancy grade based on histology 25, 39 . Importantly, however, a subset of IDH-wild-type diffuse astrocytomas share molecular similarities with pilocytic astrocytoma or other paediatric low-grade gliomas, and are associated with favourable survival outcomes 12 . Thus, in patients with disease initially classified as IDH-wild-type diffuse or anaplastic astrocytoma, additional molecular testing for genetic aberrations associated with either IDH-wild-type glioblastoma, (for example, TERT-promoter mutations, EGFR amplification, loss of chromosome 10 and gain of chromosome 7), or pilocytic astrocytoma (such as KIAA11549-BRAF fusion) can provide diagnostically useful information 40 (TABLE 1) .
IDH-mutant astrocytic gliomas. IDH mutation is probably among the earliest genetic aberrations that occur during the development of glioma 11 ; however, findings in mice indicate that IDH mutation alone is not sufficient for tumorigenesis 41 . Indeed, IDH-mutant astrocytomas commonly carry additional mutations in
Key points
• The 2016 WHO Classification of Tumours of the Central Nervous System reflects a paradigm shift, replacing traditional histology-based glioma diagnostics with an integrated histological and molecular classification system that enables more-precise tumour categorization • The requisite diagnostic biomarkers in the 2016 WHO classification of gliomas are IDH1/2 (IDH) mutations, 1p/19q codeletion, H3F3A or HIST1H3B/C K27M (H3-K27M) mutations and C11orf95-RELA fusions • Additional diagnostically relevant biomarkers include loss of nuclear ATRX expression, TERT-promoter mutations, KIAA1549-BRAF fusions, BRAF-V600E mutation, H3F3A-G34 mutation, and several other alterations associated with rare glioma entities • MGMT-promoter methylation is predictive of benefit from alkylating chemotherapy in patients with IDH-wild-type glioblastoma; predictive biomarkers for targeted therapies, such as IDH1 and BRAF mutations, are also emerging • Novel methods for large-scale DNA-methylation, copy-number and mutational profiling will further advance the assessment of glioma-associated molecular biomarkers • Clinical trials require assessment of molecular biomarkers as criteria for study entry and/or patient stratification; predictive DNA sequencing followed by targeted therapy will support the implementation of precision medicine in neuro-oncology TP53 and ATRX 10, 11 , indicating that the development of IDH-mutant astrocytoma requires multiple genetic 'hits' . ATRX mutation typically leads to an immunohistochemically detectable loss of nuclear expression of the transcriptional regulator ATRX (FIG. 2a) , which has important roles in chromatin remodelling and regulation of telomere length 42 . Genetic alterations associated with progression from diffuse (WHO grade II) to anaplastic (WHO grade III) astrocytoma and, eventually, IDH-mutant (secondary) glioblastoma are variable, and include chromosomal 9p21 deletions involving CDKN2A (encoding both cyclin-dependent kinase inhibitor 2A, also known as p16
INK4A
, and ARF, also known as p14 ARF ) and CDKN2B (encoding cyclin-dependent kinase 4 inhibitor B, also known as p15 INK4B ), deletion of 19q, and a variety of other chromosomal imbalances 40 . Other aberrations have been implicated in progression of IDH-mutant gliomas, including: activation of MYC and the receptor tyrosine kinase (RTK)/RAS/PI3K pathway; upregulation of forkhead box protein M1 (FOXM1) expression and E2F2-dependent cell-cycle progression; and epigenetic silencing of developmental transcription factor genes regulated by the polycomb repressive complex 2 (PRC2) 43 . Accumulation of somatic mutations in genes that encode inhibitors of the G1/S cell-cycle checkpoint, including members of the retinoblastoma (Rb) pathway, and low levels of methylation at CpG sites in regulatory regions of genes involved in cell-cycle progression (such as TP73), further implicate dysregulated cell division as a point of convergence of the molecular events driving progression 12, 44 .
IDH-mutant and 1p/19q-codeleted oligodendroglial tumours. Oligodendrogliomas are genetically defined by the presence of coexistent IDH mutation and whole-arm codeletion of chromosome arms 1p and 19q (FIG. 2b) the latter aberration is caused by an unbalanced t(1;19) (q10;p10) translocation [45] [46] . Activating mutations in the TERT-promoter region (which lead to aberrant expression of telomerase reverse transcriptase) 47 are present in >95% of oligodendroglial tumours, and CIC mutation (resulting in inactivation of the protein homologue of Drosophila capicua, a transcriptional repressor) is detectable in more than two thirds of patients 48 . Mutations in FUBP1 (encoding far upstream element-binding protein 1, which is involved in regulating MYC expression) are found in approximately one-third of oligodendroglial tumours 48 (TABLE 1) . Lesscommon alterations affect developmental pathway genes, predominantly NOTCH1; genes encoding epigenetic regulators, such as SETD2; and PI3K pathway genes, for example, PIK3CA (REFS 10, 11) . Genetic alterations that have been linked to a more-aggressive disease phenotype include 9p21 deletions 49 , mutations in the transcription factor 12 gene (TCF12) 50 , and aberrations resulting in activation of MYC signalling 51 .
Oligoastrocytic gliomas. In the 2016 WHO classification, oligoastrocytomas are no longer considered as separate entities because they lack a distinctive genetic profile, and instead have either astrocytic or oligodendroglial genotypes 10, 11, 27 ; thus, testing for IDH mutation and 1p/19q codeletion is required 22 . Classification as oligoastrocytoma (or anaplastic oligoastrocytoma), not otherwise specified (NOS) is restricted to rare instances in which molecular testing remains inconclusive or could not be properly performed 22 (TABLE 2) . Individual cases of IDH-mutant 'oligoastrocytoma' consisting of spatially and genetically distinct populations of oligodendroglial cells with 1p/19q codeletion together with astrocytic cells without 1p/19q codeletion, but with loss of nuclear ATRX expression have been reported 52 ; however, such disease is not recognized as a separate entity in the WHO classification 22 .
IDH-wild-type glioblastoma. IDH-wild-type glioblastomas (WHO grade IV) can arise in individuals of any age, but predominantly occur in patients >50 years of age. These tumours typically manifest as 'primary glioblas tomas' -that is, glioblastomas that present with a short clinical history of usually <3 months before diagnosis and without the detection of a pre-existing lowergrade glioma 22 . Glioblastomas that develop de novo in nonmidline locations in patients ≥55 years of age can be diagnosed as IDH-wild-type glioblastomas when IDH1-R132H is not detected using immunohistochemistry 22 . In patients aged <55 years and in patients with clinical evidence of pre-existing low-grade glioma, exclusion of other IDH mutations is required -for example, via DNA sequencing -in order to fully rule out IDH-mutant glioblastoma 22 . IDH-wild-type glioblastomas in adults are characterized by frequent gain of chromosome 7, monosomy of chromosome 10, mutation or homozygous deletion of PTEN, homo zygous deletion of CDKN2A and CDKN2B, and TERT-promoter mutations 53 (TABLE 1); other less-common alterations include mutations in TP53, PIK3CA, PIK3R1 (encoding PI3K-regulatory subunit 1), and NF1 (encoding neurofibromatosis type 1) 9 . Gene amplifications are also commonly detected in IDH-wild-type glioblastomas, and involve the EGFR, PDGFRA, and MET genes encoding mitogenic RTKs; the cyclin-dependent kinase genes CDK4 and CDK6 that mediate transition from G1 to S phase of the cell cycle; and MDM2 and MDM4, which encode proteins ; FIG. 2c) , which lacks the extracellular ligand-binding region encoded by the deleted exons, but is constitutively active 53 . BRAF-V600E encodes a druggable mutant protein, and is detectable in approxi mately 50% of epithelioid (FIG. 2d) , a newly described provisional variant of IDH-wild-type glioblastoma. Giant-cell glioblastoma and gliosarcoma are other histological variants of IDH-wild-type glioblastoma 22 (TABLE 2) .
IDH-mutant glioblastoma. The IDH-mutant glioblastoma subtype accounts for <10% of all glioblastomas and is typically manifest in young adults 22 . These tumours include almost all secondary glioblastomas that develop via progression from pre-existing lower-grade gliomas. Consequently, the molecular profile of this class of gliomas is similar to that of IDH-mutant astrocytomas, including frequent TP53 and ATRX mutations, alongside a G-CIMP 53 (TABLE 1) . Lower levels of DNA methylation compared with those usually present in IDH-mutant and G-CIMP-positive astrocytic gliomas have been detected in a subset of patients, and are associated with an unfavour able outcome 12 . The prognosis of patients with IDH-mutant glioblastoma is, however, typically betterwith a greater likelihood of long-term survival -than that of patients with IDH-wild-type glioblastoma, owing to a younger mean age at diagnosis, a higher frequency of MGMT-promoter methylation, and other, yet to be identified factors 34, 53 . Molecular subgroups of adult glioblastoma. mRNAexpression analyses have revealed four distinct subtypes of glioblastoma: proneural, neural, classic and mesenchymal 55 . The clinical utility of stratifying patients according to these expression signatures is limited, however, as they can be heterogeneous within a given tumour and can change in response to external stimuli, including therapy 56, 57 . Nevertheless, the mesenchymal expression signature has been linked with radioresistance and unfavourable survival 56 , whereas the proneural signature has been associated with a benefit from antiangiogenic treatment in patients with IDH-wild-type glioblastoma 58 . DNA-methylation profiles can be used to robustly distinguish glioblastoma subgroups associated with specific epigenetic patterns and gene-expression profiles 8, 9 . Four major subgroups of adult glioblastoma have been identified, including an IDH-mutant, G-CIMP-positive, and typically MGMT-promoter-methylated subgroup with a proneural gene-expression profile, and three subgroups of IDH-wild-type glioblastoma (FIG. 3) . Among the IDHwild-type glioblastoma subgroups, 'receptor tyrosine kinase I' (RTK I) glioblastomas predominantly occur in adolescents and young adults, and are characterized by PDGFRA amplification and a proneural gene-expression profile. The 'receptor tyrosine kinase II' (RTK II) and the 'mesenchymal' IDH-wild-type glioblastoma subtypes predominate in patients >50 years of age, and are distinguished by different DNA-methylation profiles, as well as fewer copy-number abberations and a mesenchymal gene-expression signature in mesenchymal glioblastoma (versus a 'classic' profile in RTK II glioblastoma) 8 (FIG. 3) .
Molecular genetics of paediatric gliomas
Paediatric gliomas comprise three major disease groups: firstly, tumours with circumscribed growth patterns that often harbour BRAF aberrations; secondly, tumours with 
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Other gliomas
Chordoid glioma of the third ventricle II Angiocentric glioma I Astroblastoma -NOS categories are reserved for the rare instancies that a tumour cannot be molecularly tested or that test results remain inconclusive 22 . H3-K27M, K27M-mutated histone H3; NOS, not otherwise specified. *Provisional tumour entities or variants. ‡ The diagnosis of 'oligoastrocytoma, NOS' or 'anaplastic oligoastrocytoma, NOS' is discouraged in the 2016 WHO classification of gliomas 22 : oligoastrocytic (mixed) gliomas should be assigned either to an astrocytic or an oligodendroglial tumour entity via appropriate molecular testing for IDH1/2 mutation and 1p/19q codeletion. § The pilomyxoid astrocytoma variant is not assigned to a definite WHO grade.
diffuse growth patterns and frequent alterations in FGFR1, or rearrangement of MYB, or the MYBL genes; thirdly, a heterogeneous group of malignant gliomas, including tumours with mutations in histone-H3-family genes.
Gliomas with circumscribed growth
Pilocytic astrocytoma. The most common form of glioma with circumscribed growth, pilocytic astro cytoma (WHO grade I), is characterized by genetic alterations that result in activation of MAPK signalling 15 (TABLE 1) ; fusion of the BRAF and KIAA1549 genes on chromosome 7q is common, particularly in cerebellar tumours (FIG. 2e) , and has been associated with favourable patient outcomes 59 . Subsets of pilocytic astrocytomas carry fusions involving different MAPK-pathway genes, such as RAF1, PTPN11, or NTRK2, or harbour mutations in BRAF, KRAS, FGFR1, or NF1 15 . Mutations in non-MAPK-pathway genes are usually absent, making pilocytic astrocytoma a 'single-pathway disease' 15 . Pilomyxoid astrocytoma is a rare histological variant of pilocytic astrocytoma that is associated with a higher likelihood of local recurrence and cerebrospinal spread than classic pilocytic astrocytoma 22 (TABLE 2) .
Pleomorphic xanthoastrocytoma. Pleomorphic xantho astrocytoma (PXA) is typically associated with BRAF-V600E mutation, often occurring together with homozygous deletion of CDKN2A and loss of p16 INK4A expression [60] [61] [62] (TABLE 2) . Genetic alterations that drive progression of WHO grade II PXA towards WHO grade III anaplastic PXA are poorly defined, as is the relationship between anaplastic PXA and epithelioid glioblastomas, which also harbour BRAF-V600E mutations 63 .
Subependymal giant-cell astrocytoma. The development of subependymal giant-cell astrocytoma (WHO grade I) is closely linked with aberrations affecting the tuberous sclerosis complex (TSC); the typical genetic changes include mutation and allelic losses leading to loss of either hamartin (TSC1) or tuberin (TSC2) expression (TABLE 1) , resulting in activation of the mTOR-signalling pathway 64 .
Well-differentiated diffuse gliomas
Unlike their adult counterparts, diffuse gliomas in children usually lack both IDH mutation and 1p/19q codeletion 16, 65 . Subsets of paediatric diffuse gliomas harbour FGFR1 alterations, rearrangements of MYB or the MYBL genes, or BRAF aberrations 16, 66 (TABLE 1) , but are not considered as distinct entities or variants in the 2016 WHO classification 22 . These tumours typically portend a favourable prognosis and malignant progression is uncommon. Angiocentric glioma, a rare WHO grade I glioma with infiltrative growth in children and young adults, is characterized by MYB-QKI fusion rearrangements that Malignant gliomas and glioblastomas H3-K27M-mutant diffuse midline glioma is a WHO grade IV glioma typically located in the thalamus, brain stem, or spinal cord 22 . This disease entity includes >70% of diffuse intrinsic pontine gliomas (DIPGs) in children 14 .
The genetic hallmark of these tumour types, K27M mutation in the histone-H3-encoding genes H3F3A or HIST1H3B/C 13, 14 , leads to global reduction of cellular histone H3 lysine 27 (H3-K27) trimethylation (FIG. 2f) via impaired recruitment of PRC2 and inhibition of the histone-lysine N-methyltransferase EZH2 (REFS 68, 69) . Of note, findings from preclinical studies with GSK-J4, which inhibits lysine-specific demethylase 6B (a Jumonji-C-domain-containing histone-lysine demethylase), and panobinostat, a pan-histone-deacetylase inhibitor, suggest the potential of epigenetic therapy in the treatment of H3-K27M-mutant gliomas 70, 71 . H3-K27M-mutant gliomas frequently harbour mutations in TP53 and/or PPM1D (encoding magnesiumdependent protein phosphatase 1D); amplification of proto-oncogenes, such as PDGFRA, MYC, MYCN, CDK4, Nature Reviews | Clinical Oncology CDK6, or CCND1-3 (encoding cyclins D1-3), ID2, and MET is also common 13, 14, 18 (TABLE 1; FIG. 3 ). Approximately 20% of DIPGs carry activin receptor 1 gene (ACVR1) mutations, whereas FGFR1 alterations are mostly associated with thalamic tumours 14, 18 . H3F3A-K27M-mutant DIPGs differ from their HIST1H3B-K27M-mutant counterparts owing to the presence of a proneural versus a mesenchymal gene-expression profile, and the former have been associated with a less-favourable outcome than the latter 72 . Hemispheric malignant gliomas in children comprise different molecular subgroups, including H3F3A-G34-mutant tumours and a small fraction of IDH-mutant glioblastomas (~6% of paediatric glioblastomas in one series) 21 (FIG. 3) . IDH-wild-type glioblastomas with genetic profiles similar to those of IDH-wild-type glioblastomas in adults also occur in children, and are associated with an unfavourable prognosis 21 ; however, approximately 20% of paediatric glioblastomas have prognostically favourable epigenetic profiles related to PXA or well-differentiated (low-grade) paediatric gliomas 21 .
Molecular genetics of ependymal tumours
Data from a study published in 2015 have revealed nine distinct biological subgroups of ependymomas, consisting of three subgroups each among spinal, posterior fossa, and supratentorial tumours 20 . Prognostically favourable tumours with subependymoma-like molecular profiles can occur at each of these anatomical sites.
More than two-thirds of supratentorial ependymomas in children carry gene rearrangements that result in fusion proteins involving the NF-κB subunit RELA and C11orf95 (REFS 19, 20) (TABLE 1) . These RELA-fusionpositive tumours, which have an aberrant NF-κB transcriptional programme and an unfavourable prognosis, constitute a novel entity in the 2016 WHO classification 22 (TABLE 2) . Less commonly, supratentorial ependymomas harbour YES-associated protein 1 (YAP1) fusions (TABLE 1) , and these tumours are associated with more-favourable outcomes 20 . Among posterior fossa ependymomas, a prognostically unfavourable subgroup (PF-A) is characterized Nature Reviews | Clinical Oncology
PXA-like
LGG-like H3-K27 ‡ H3-G34 • H3-K27M mutation by genomic stability; tumours in this subgroup are probably driven mainly by epigenetic mechanisms, as recurrent genetic alterations have not been identified 20 (TABLE 1) . Another subgroup (PF-B) has chromosomal instability, but a clinically less-aggressive phenotype 20, 73 . Spinal ependymomas are mostly indolent tumours, with intramedullary ependymomas frequently demonstrating NF2 mutations (TABLE 1) , while myxopapillary ependymomas of the filum terminale often show multiple numerical chromosome aberrations 20 . Among all ependymoma subgroups, RELA-fusion-positive supratentorial ependymomas and PF-A ependymomas are associated with the worst outcomes, as indicated by a 10-year overall survival of approximately 50% in patients with these tumours subtypes, compared with 88-100% in those with the other ependymoma subtypes, in a large restrospective cohort 20 .
Glioma biomarkers Entity-defining molecular biomarkers
The 2016 WHO classification of gliomas incorporates IDH1/2 mutation, 1p/19q codeletion, H3-K27M mutation and C11orf95-RELA fusion as diagnostic biomarkers that define distinct glioma entities (TABLE 2) . Other biomarkers can provide additional diagnostic information, including loss of nuclear ATRX expression, TERTpromoter mutation, BRAF mutation or fusion, and H3-G34 mutation 30, 40 . If molecular testing cannot be performed, or the results remain inconclusive, the term 'NOS' (not otherwise specified) has been introduced to indicate that the diagnosis is based on histology onlythat is, information on the relevant biomarker(s) was not available for an integrated diagnosis (TABLE 1) 22, 30 .
Predictive molecular biomarkers
The number of biomarkers of predictive significance for guiding the post-surgery treatment of patients with glioma is increasing 74 . Among these, the presence of MGMT-promoter methylation is predictive of benefit from alkylating-agent chemotherapy in patients with IDH-wild-type glioma, particularly in elderly patients (aged ≥70 years) 75, 76 . Long-term follow-up studies of two phase III trials in patients with anaplastic glioma have revealed that 1p/19q codeletion is a predictive marker of benefit from upfront combined radiotherapy and chemotherapy with procarbazine, lomustine (CCNU), and vincristine (PCV) 77, 78 . Other genetic aberrations are emerging as potential predictive biomarkers of responsiveness to glioma therapy 40 (TABLE 3) .
MGMT-promoter methylation. The DNA-alkylating agent temozolomide is the standard drug used in concomitant radiochemotherapy and maintenance chemotherapy for glioblastoma 79 . A major temozolomide-induced DNA-adduct, 6-O-methylguanine, is effectively repaired by 6-O-methylguanine-DNA methyltransferase (MGMT; also known as methylated-DNA-protein-cysteine methyltransferase), via alkylation of MGMT itself, followed by ubiquitylation and subsequent proteasomal degradation of this enzyme 80 . Thus, MGMT expression levels correspond to the cellular 6-O-methylguanine-repair capacity, and tumour cells with low or absent MGMT expression are rendered more sensitive to temozolomide 80 . Approximately 40% of IDH-wild-type glioblastomas have hypermethylation of an MGMT-associated 5ʹ CpG island, which results in transcriptional repression and reduced MGMT expression 80 . This epigenetic change is known as MGMT-promoter methylation, and has been closely linked with benefit from temozolomide therapy and prolonged survival of patients with glioblastoma 3, 81 . Moreover, phase III trials in patients aged >65 years with glioblastoma revealed that MGMT-promoter methylation is a highly relevant biomarker for guiding treatment decisions between the use of radiotherapy or temozolomide chemotherapy 75, 76 . The predictive role of MGMT-promoter methylation for a response to temozolomide might be restricted to those with IDH-wild-type gliomas, however. MGMT-promoter methylation is present in most IDH-mutant and G-CIMP-positive gliomas, and portends a favourable prognosis in these settings, but is not linked with differential benefit from either temozolomide or radiotherapy 82 .
MGMT-promoter methylation usually occurs homogeneously within different regions of an individual glioma 83 , and remains stable over the course of the disease 84 . Nevertheless, tumours with MGMT-promoter methylation can acquire secondary temozolomide resistance owing to mutations that drive clonal evolution and tumour recurrence. For example, mutations in DNA-mismatch-repair genes can cause a hypermutator genotype 85 . Despite the clinical significance of MGMT-promoter methylation, diagnostic testing remains challenging owing to heterogeneous methylation of MGMT-associated CpG sites between different tumours, unclear thresholds for defining 'positivity' in tumours with weakly or borderline detectable MGMTpromoter methylation, and the use of diverse, nonstandardized testing methods 40, 80 . Thus, harmonization of test protocols and the establishment of internal and external quality assessments are important to ensure the robustness of diagnostic results.
1p and 19q codeletion. 1p/19q codeletion has been implicated as an independent predictive biomarker of benefit from the addition of PCV chemotherapy to upfront treatment with irradiation in patients with anaplastic glioma 77, 78 . The mechanisms underlying the favourable treatment responses and the good long-term survival of patients with IDH-mutant and 1p/19q-codeleted gliomas (median overall survival of >10 years) are poorly understood. Of note, only whole-arm 1p/19q codeletion combined with IDH mutation is prognostically favourable; partial deletions on either chromosome arm, which can occur in those with IDH-wild-type glioblastomas, are associated with poor patient outcomes 86 .
Emerging predictive biomarkers. BRAF-V600E mutation has emerged as a promising predictive biomarker of a response to BRAF inhibitors in patients with glioma 87 . Similarly, detection of IDH mutation is important to identify patients suitable for evaluation of treatments with inhibitors of mutant IDH 88 , or peptide-based vaccination targeting IDH1-R132H 89 in clinical trials. Likewise, treatments targeted at EGFR or EGFRvIII would require predictive testing for EGFR amplifications or EGFRvIII positivity [90] [91] [92] [93] [94] . Another potential predictive biomarker is the presence of FGFR-TACC fusions, which might enable the identification of patients with glioblastoma who are potentially eligible for FGFR-inhibitor therapy 95, 96 .
Novel molecular diagnostic approaches
Each of the biomarkers we have discussed can be assessed using tests predicated on a single protein or gene, involving immunohistochemistry, fluorescence in situ hybridization, DNA sequencing, or other methods 40 . However, the advent of high-throughput technologies for molecular testing, including micro array-based procedures and next-generation sequencing (NGS), provides promising opportunities for the development of novel diagnostics
. At present, application of whole-exome or whole-genome sequencing is mostly restricted to research projects and selected clinical trials -for example, the INFORM trial in paediatric patients 97 , or the NCT Neuro Master Match (N 2 M 2 ) and NCI-MATCH trials in adult patients 98, 99 . However, NGS of brain-tumour-tailored gene panels, typically covering between ~20 to ~150 genes that are known to be mutated in gliomas and/or other types of brain tumours, is already performed in clinical practice at some centres [100] [101] [102] [103] . This technique can be applied to routinely processed tissue samples, and enables sequencing of diagnostically relevant genes, as well as the identification of actionable mutations with a high level of sensitivity and specificity. Thus, fast and robust parallel analysis of multiple markers can be achieved at affordable costs. Another complementary approach involves DNA-methylation profiling using microarray technology, which has revealed distinct molecular subgroups among anaplastic gliomas 25 , glioblastomas 8, 21 , and ependymal tumours 20 as described in previous sections of this Review. Use of this approach has also revealed that gliomatosis cerebri is not a distinct entity 28 . Moreover, copy-number alterations across all chromosomes and MGMT-promoter methylation status can be assessed in parallel with DNA-methylation profiles using different bioinformatics algorithms for analysis of the microarray data 25, 104 . The use of these and other advanced molecular assays will soon become a widespread practice.
The current WHO classification of glioma relies exclusively on assessments of tumour tissue; however, 'liquid biopsy' approaches involving ultra-deep sequencing of DNA from cerebrospinal fluid or plasma, for example, hold promise for less-invasive approaches to the diagnosis and disease monitoring of various cancers, including gliomas [105] [106] [107] . Glioma-associated micro-RNAs, such as miR-21, can also be detected in cerebrospinal fluid, and could potentially serve as diagnostic, prognostic, and/or predictive biomarkers 108, 109 .
Current multimodal therapy of gliomas
Despite tremendous advances in our understanding of glioma genetics, molecularly targeted therapies have, to date, failed in phase III trials in patients with this disease, and the classic treatment modalities of surgery, radiotherapy, and/or chemotherapy remain the mainstay of therapy 34, 74 . Surgery can be curative in patients with circumscribed gliomas, such as pilocytic astrocytoma, PXA, and subependymal giant-cell astrocytoma (FIG. 4) . Most ependymomas also have circumscribed patterns of growth, but local brain invasion is common and the risk of dissemination within the CNS increases with the duration of the disease; therefore, complete resection
Box 2 | High-throughput technologies for the molecular diagnosis of glioma
Microarray-based DNA-methylation profiling Can provide information on diagnostic DNA-methylation profiles and DNA copy-number alterations (CNAs).
• Advantages: applicable to formalin-fixed paraffin-embedded (FFPE) material; no blood-cell-derived DNA required as a reference; relatively inexpensive • Limitations: cannot detect subtle alterations, such as point mutations
Sequencing of glioma-associated gene panels
Provides information on mutations and CNAs of selected cancer-related genes.
• Advantages: applicable to FFPE material; small gene panels might not require analysis of blood-cell-derived DNA as a reference; enables high sequence coverage from very low amounts of DNA; relatively inexpensive • Limitations: cannot detect DNA-methylation changes, such as MGMT-promoter methylation Diagnostic whole-exome or whole-genome sequencing Provides information on mutational profiles across all coding exons or the entire genome of a given tumour.
• Advantages: provides a comprehensive overview of mutations, CNAs, and complex chromosomal rearrangements • Limitations: requires blood-cell-derived DNA for reference; requires bioinformatics expertise; expensive (compared with target-gene approaches); cannot detect DNA-methylation changes, such as MGMT-promoter methylation is prognostically favourable, but consolidating radiotherapy is often required for prolonged tumour control in patients with anaplastic ependymoma and following incomplete resection of WHO grade II ependymoma 110 . Gross total resection is also associated with improved survival of patients with diffuse gliomas, including glioblastoma 111, 112 , and this improved survival also applies to the growing group of elderly patients 75, 113 . Nevertheless, diffuse gliomas generally recur after resection; therefore, additional treatment aimed at prolonging survival while maintaining quality of life is the standard of care. The optimal choice and timing of the various available treatments depends on patient age, clinical performance status, tumour entity, and molecular biomarkers (FIG. 4) . Postsurgical radiotherapy provides improved local control in patients with diffuse gliomas of any grade when compared with surgery alone. Furthermore, radiotherapy prolongs the survival duration of patients with WHO grade III or IV glioma and is, therefore, the standard of care for these patients 74 . Delaying radiotherapy until recurrence after surgery does not compromise overall survival in patients with WHO grade II gliomas 114 , but such 'watchful waiting' strategies should only be considered appropriate for patients aged <40 years, with favourable prognostic features 115, 116 (FIG. 4) . The RTOG 9802 trial 117 results demonstrated that patients with WHO grade II diffuse gliomas considered to require treatment beyond surgery had prolonged overall survival durations when PCV polychemotherapy was added to radiotherapy. By contrast, the EORTC 22033-26033 trial 118 , in which the efficacy of radiotherapy alone was compared with that of chemotherapy alone did not result in the identification of any patient subgroup that derived a greater benefit from either treatment over the other.
1p/19q codeletion is a predictive biomarker of longterm benefit from PCV polychemotherapy administered immediately before or after radiotherapy in patients with anaplastic glioma 77, 78 (FIG. 4a) . Whether the PCV regimen can be effectively replaced by temozolomide will be explored in the new CODEL trial 119 . Whether the benefit from adding PCV to radiotherapy observed in a subset of patients with tumours lacking 1p/19q codeletion is linked more closely to IDH mutation 120 or MGMT-promoter methylation 121 remains controversial. Nevertheless, preliminary data from the CATNON trial 122 have confirmed a role of early maintenance alkylating chemotherapy with temozolomide after radiotherapy in patients with anaplastic glioma lacking 1p/19q codeletion.
Postoperative chemoradiotherapy, with 60 Gy in 30 fractions and concomitant daily temozolomide, followed by six cycles of maintenance temozolomide (TMZ/RT→TMZ ; FIG. 4a,b) is the standard of care for patients with glioblastoma 74, 79 . This treatment approach was established based on the results of a trial that did not include patients aged >70 years 79 , and data from subgroup analyses have suggested only limited benefits from the addition of temozolomide to radiotherapy in patients aged 65-70 years 123 . Trials in elderly patients (variably defined as patients aged ≥60-70 years) with glioblastoma, who have a particularly poor prognosis, demonstrated the efficacy of shorter, hypofractionated radiotherapy regi mens in this population 123, 124 , and a predictive role of MGMT-promoter methylation for benefit from first-line temozolomide alone 75, 76 . Nonetheless, elderly patients with MGMTpromoter-methylated tumours who are eligible for combined modality treatment can benefit from the TMZ/RT→TMZ regimen 125 . 
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The definition of standards of care at glioma recurrence remains challenging. Gross total resection does prolong overall survival durations in patients with recurrent glioblastoma 126 , but the value of repeat surgery is less clear in patients with other gliomas. The use of surgery merely to reduce tumour volume -rather than with the aim of achieving gross tumour resection -is under debate because the validity of the retrospective studies suggesting beneficial effects, compared with no repeat surgery, is challenged by major imbalances in prognostic factors between the treatment cohorts 74 . Radiotherapy at recurrence is an option for patients who did not receive first-line radiotherapy, but is limited by neurotoxic dose-accumulation effects that can cause radionecrosis 127 . Systemic treatments that can be used at disease recurrence include alkylating agent chemotherapy, mostly with lomustine 128, 129 , or rechallenge with temozolomide in patients with MGMT-promoter methy lation and apparent benefit from first-line treatment with this agent 130, 131 ; however, effects on survival are moderate at best. In the USA and some other countries, antiangiogenic therapy with beva cizumab was approved for the treatment of recurrent glioblastoma based on radiographic response rates in the range of 20-40% -and presumed clinical benefit -in two uncontrolled trials 132, 133 ; approval was conditional on the subsequent demonstration of an overall survival bene fit, which was achieved neither in studies in patients with newly diagnosed glioblastomas 4, 5 , nor when bevacizumab was combined with lomustine in the treatment of patients with recurrent disease 134 . Application of 'tumour treating fields' (TTF), that is, alternating electric fields that are applied via skin electrodes placed on the shaved scalp, prolonged the survival of patients with newly diagnosed glioblastoma in a phase III trial 135 ; however, scepticism surrounds this approach, owing to trial design issues, the uniformity of results across subgroups, and a small effect-magnitude relative to the potentially major adverse effects on quality of life 136 .
Mechanisms of progression after therapy
Gliomas are characterized by intratumoural heterogeneity, owing to the presence of cells with distinct profiles of molecular aberrations, which might facilitate malignant progression and therapy resistance. IDH mutations are generally retained in recurrent tumours 43, 137 , thus underscoring the role of these alterations as tumour-initiating events (that is, 'driver' mutations) and as potential therapeutic targets. The IDH-mutation-associated G-CIMP is usually also maintained at disease recurrence 44 ; however, malignant progression can be accompanied by a reduction in the frequency of methylated CpG sites, and rare tumours show loss of G-CIMP at recurrence, which has been associated with poor outcomes 12 . By contrast, increased DNA methylation upon glioma progression has been observed at a small fraction of CpG sites, particularly those in genes encoding developmental transcription factor families with key roles in pattern formation and cell-fate determination. Notably, the patterns of hypermethylated CpGs required for maintenance of the human embryonal stem-cell (hESC) phenotype are enriched upon progression towards glioblastoma, including the promoters of genes that are strongly silenced in hESC as a result of H3-K27 trimethylation 43 . Thus, a high grade of histological malignancy is associated with stem-like features, a finding that supports the hypothesis that stem-like cells mediate resistance to chemotherapy and/or radiotherapy, as derived mostly from studies of IDH-wild-type glioblastomas [138] [139] [140] . The lack of a defining molecular marker profile challenges the prospective identification and in situ characterization of such stemlike cells. Instead, models of glioma stem-like cells rely on enrichment strategies based on the use of single or multiple biomarkers for segregation, for example, CD15, CD44, or CD133 (REF. 141 ). Marker-positive cells are then propagated in the brains of immune-compromised mice, or in vitro under growth conditions that promote either stem-cell or non-stem-cell growth, to retrospectively confirm enrichment of stem-like traits; however, selection and epigenetic biases must be considered when interpreting data from these models 56 . Genetic differences between glioma stem-like and non-stemlike cells have not been defined, although an epigenetic pattern resembling that of paediatric glioblastomas with H3F3A mutation is characteristic of CD133-positive stem cells 142 . Data from single-cell mRNA-expression studies have revealed a dynamic distribution of stem-like versus more-differentiated traits, contributing to glioblastoma intratumour heterogeneity 57 . Depletion of glioma stem-like cells, via targeted disruption of CD44 or the nuclear receptor tailless (Tlx), resulted in improved survival in preclinical models 143, 144 ; however, in early clinical trials that evaluated therapies targeting glioma stem-like cells, the inhibitor of Sonic hedgehog signalling vismodegib, and the inhibitor of Notch signalling RO4929097 failed to induce durable tumour responses 145, 146 . Clonal selection during malignant progression can favour cells that lack mutations present in the initially predominant clones (including oncogenic drivers, such as TP53, ATRX, FUBP1, SMARCA4, and BRAF) 43, 137 , indicating that alternative pathways of progression can diverge at early stages of tumour evolution, even without the selective pressure inferred by anticancer treatments. Temozolomide chemotherapy can, however, contribute to malignant progression by inducing a hyper mutation state that is associated with driver mutations in components of the Rb and mTOR pathways 137 . Defects in genes encoding DNA-mismatch-repair proteins are thought to underlie the hypermutation state, and could potentially be used to identify patients at risk of therapy-associated malignant progression 147 . Indeed, MGMT-promoter methylation status is essentially unaffec ted by progression of glioblastomas after treatment with the TMZ/RT→TMZ regimen 82 , thus implicating alternative mechanisms of temozolomide-resistance including DNA-mismatch-repair deficiency leading to DNA hypermutation 84, 85, 137 . Resistance of diffuse gliomas to radiotherapy can be mediated by activation of the DNA-damage response 139, 148 , and a rapid radiotherapy-induced switch towards a mesenchymal gene-expression pattern that results in enhanced pro-survival signalling via NF-κB to counteract proapoptotic signals 56, 149 . Formation of an interconnecting microtubule network between glioma cells has been proposed as a new mechanism of radioresistance 150 . Ultimately, large sets of well-annotated, matched samples from individual patients collected before and after therapy will be required to characterize the molecular basis of glioma chemotherapy and radiotherapy resistance.
Novel pathogenesis-based treatments
Targeting oncogenic signalling pathways Improvements in our understanding of the molecular mechanisms that underlie gliomagenesis have prompted attempts to target identified drivers of the disease. Such approaches are particularly promising in circumscribed gliomas that are driven by activation of a single pathway. For example, treatment with the mTOR-inhibitor everolimus is effective in patients with subependymal giant-cell astrocytomas, in terms of reductions in tumour volumes and seizure frequencies 151, 152 , and responses to the BRAF inhibitor vemurafenib have been reported in patients with BRAF-V600E-positive recurrent PXA 153, 154 . A clinical trial investigating the efficacy of vemurafenib is ongoing in paediatric patients with BRAF-V600E-positive recurrent malignant gliomas 155 . A phase I/II trial of dabrafenib 156 , an inhibitor of mutant BRAF, in paediatric patients with BRAF-V600E-mutant relapsed or refractory low-grade gliomas has revealed promising activity, with an objective response rate of 41%. By contrast, preclinical studies in KIAA1549-BRAF-fusion-positive cells have revealed that PLX4720, an analogue of vemurafenib, induced paradoxical activation of MAPK signalling 157 . Similarly, sorafenib treatment resulted in paradoxical MAPK-pathway activation and accelerated tumour growth in patients with pilocytic astrocytoma 158 . Use of the MAPK-pathway inhibitor selumetinib might circumvent this limitation, and this agent is currently under clinical investigation for the treatment of patients with pilocytic astrocytomas 159 . The more-diverse biology of ependymomas suggests that similarly straightforward treatment approaches might not be effective in patients with this disease, but trials of everolimus, or hormone-receptor blockade in patients with HER2-positive ependymoma, are ongoing 34 . In glioblastoma, a complete response to vemurafenib noted in a paediatric patient with BRAF V600E -positive glioblastoma provides further proof of principle for targeting aberrant signalling pathways 160 . Other examples include the association of benefit from therapy using the mTOR inhibitor temsirolimus with phosphorylation of the downstream mTOR target ribosomal protein S6 kinase β1 (S6K1), as detected in tumour samples from patients with recurrent glioblastoma 161 , and with mTOR S2448 phosphorylation detected in tumour specimens from those with newly diagnosed MGMT-unmethylated glioblastoma (in post hoc analyses) 162 . Efficacy studies using these molecular entry criteria are, however, not underway.
Overall, the targeted inhibition of oncogenic signalling has not proven effective in randomized controlled trials involving patients with glioblastoma 129, 162, 163, 164 . Several early trials were performed to evaluate the efficacy of EGFR inhibitors in patients with diffuse gliomas, but none monitored for the presence of EGFR amplification in tumour cells as a potential predictive biomarker of responsiveness 165 . In a promising therapeutic approach, EGFR amplification has been exploited to deliver the microtubule toxin monomethyl auristatin F using a drug-conjugated antibody (ABT-414) directed specifically at the activated conformation of EGFR 166 .
Resistance to oncogenic signalling inhibitors is related to clonal diversity, which can be bypassed by targeting aberrations that occurred early in tumorigenesis and thus are shared by all (or almost all) tumour cells. IDH mutation is a key example of this type of oncogenic aberration. Indeed, preclinical data indicate that small-molecule inhibitors of mutant IDH proteins can reverse the G-CIMP signature, induce glial differentiation, and inhibit the growth of IDH-mutant glioma cells 88 . Early stage clinical trials of such agents are ongoing in patients with advanced-stage IDH-mutant malignancies, including gliomas [167] [168] [169] . The concept of epigenomic reshaping using inhibitors of H3-K27 demethylase and histone deacetylases has also been explored with promising results in preclinical models of H3-K27M-mutant paediatric brainstem gliomas 70, 71 . In IDH-wild-type glioblastomas, EGFRvIII has been identified as a driver of epigenetic remodelling that promotes tumour growth 170 , but EGFRvIII is expressed in only subsets of tumour cells and is relatively resistant to inhibitors of EGFR signalling (compared with EGFR variants carrying activating mutations) 171 , thus presenting challenges for therapeutic targeting of this aberration.
The extensive vascularity of many glioblastomas has prompted investigations of several antiangiogenic approaches to therapy, including the use of smallmolecule inhibitors of VEGF signalling, the anti-VEGF antibody bevacizumab, and inhibition of integrins by a cyclic peptide (cilengitide); however, enthusiasm for such strategies has been dampened by the negative outcomes of several phase III trials 4, 5, 134, 164 . Nevertheless, subgroup analyses of AVAGlio 58 , a placebo-controlled phase III trial designed to assess the addition of bevacizumab to standard first-line chemoradiotherapy in patients with newly diagnosed glioblastoma, indicate that a pro neural gene-expression signature might be a biomarker of benefit from antiangiogenic therapy.
In spite of the potential to identify disease drivers and the available means to target these aberrations in diffuse gliomas, mosaicism of genomic alterations 172 , clonal selection, and treatment-induced evolution, as well as dose-limiting toxicities, and other pharmacokinetic and pharmacodynamic issues complicate the clinical translation of molecularly targeted treatments 173 . Combinations of the different treatment approaches individualized according to molecular features and the clonal composition of each tumour, and possibly involving sequential biopsies, might be required to overcome the spatial and temporal heterogeneity of diffuse gliomas.
Immunotherapy approaches
Gliomas are not considered highly immunogenic because, in contrast to tumours against which immunotherapy is effective (such as melanoma or non-smallcell lung cancer (NSCLC)), mutational loads are typically low. Moreover, gliomas are characterized by profound immunosuppression mediated by secreted (such as transforming growth factor β and IL-10) and cell-surface immuno suppressive factors (for example, FAS ligand and programmed cell-death 1 ligand 1 (PD-L1)), by infiltration of immune-inhibitory cells in the tumour microenvironment, and by the anatomical peculiarities of the brain, such as the blood-brain barrier and the paucity of lymphatic vessels 174, 175 . Nevertheless, multiple strategies to overcome immunosuppression and exploit antitumour immune responses have been pursued in patients with gliomas. Firstly, vaccination -that is, immunization with tumour-specific or tumour-associated peptides, or by administration of autologous antigen-presenting cells boosted with such peptides. Secondly, immunomodulatory drugs that target T-cell-inhibitory signalling to enhance physiological antitumour responses. Finally, adoptive T-cell transfer, which involves in vitro clonal expansion or genetic engineering of T cells with high avidity for tumour-specific or tumour-associated epitopes 176 .
Vaccination. EGFRvIII has been considered a promising target yielding tumour-specific epitopes for boosting antitumour adaptive immune responses with a minimal risk of crossreactivity against nontumour cells. In combination with bevacizumab therapy, vaccination with an EGFRvIII-specific peptide, rindopepimut (also known as CDX-110), seems to prolong the survival durations of patients with EGFRvIII-positive recurrent glioblastoma, as demonstrated in an exploratory randomized phase II trial 94 . In patients with newly diagnosed EGFRvIIIpositive glioblastoma, however, overall survival was unaffected by the addition of rindopepimut to standard temozolomide maintenance therapy in the double-blind, placebo-controlled, phase III ACT-IV trial 177 . Despite this setback, EGFRvIII remains an attractive treatment target in patients with glioblastoma and continues to be explored in this context. R132H-mutant IDH is another potential target of single-peptide vaccination approaches. Epitopes containing the mutated portion of this protein are presented on MHC class II molecules and induce mutationspecific CD4 + T-cell responses, anti-IDH1-R132H CD4 + T cells and antibodies occur spontaneously in patients with IDH1-R132H-mutant glioma, and this vaccination approach evoked durable anticancer responses in a preclinical glioma model 89 . The transfer of autologous dendritic cells (DCs) pulsed ex vivo with tumour-associated peptides (or RNAs encoding such peptides) is currently being explored as an alternative vaccination strategy. For example, in 12 patients with glioblastoma, immunization with DCs pulsed with the cytomegalovirus (CMV) antigen pp65 RNA, which is expressed in >90% of glioblastomas, but not in surrounding nonmalignant brain tissue, triggered antitumour T-cell responses that were reinforced by preconditioning of the vaccine site with the recall-antigen tetanus/diphtheria toxoid 178 . Moreover, prolongation of progression-free survival by 2.4 months was reported in a placebo-controlled phase II trial exploring the addition of the DC vaccine ICT-107 to maintenance therapy for patients with newly diagnosed glioblastoma 179 . ICT-107 comprises autologous DCs pulsed with six synthetic peptides from the glioma-associated antigens MAGE-1, HER2, AIM-2, TRP-2, gp100, and IL-13Rα2; in this trial unpulsed DCs were used as the placebo 179 . A pivotal phase III trial has been launched to further evaluate this approach 180 . The use of a DC vaccine in addition to standard therapy for patients with newly diagnosed glioblastoma has also been explored in the phase III DCVax trial 181 , wherein autologous DCs were pulsed with tumour lysates derived from the same patient; however, results of this trial have not been reported to date.
Immune-checkpoint blockade. The immuno suppressive microenvironment of gliomas is a major caveat that can limit the effectiveness of immunotherapy 182 . Monoclonal antibodies directed at the inhibitory immune checkpoints mediated by cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; ipilimumab) or programmed celldeath protein 1 (PD-1; nivolumab and pembrolizumab) expressed on T cells have entered clinical practice, notably as treatments of metastatic melanoma and NSCLC [183] [184] [185] [186] . Furthermore, antibodies to PD-L1 are being developed -and one such agent, atezolizumab, has been approved by the FDA for the treatment of bladder cancer. In addition, antibodies neutralizing other immunoreceptors, such as killer-cell immunoglobulinlike receptors (KIR) or lymphocyte activation gene 3 (LAG-3) have been developed 182 . Interestingly, immunecheckpoint blockade resulted in tumour eradi cation in an immunocompetent glioblastoma model 187 , and impressive clinical responses to nivolumab have been observed in two siblings with recurrent multi focal, DNAmismatch-repair-deficient glioblastoma 188 . Current trials being conducted to evaluate the efficacy of immunomodulatory drugs in patients with glioma include the phase III CheckMate 143 trial of nivolumab and bevacizumab in patients with recurrent glioblastoma 189 , the double-blind phase II CheckMate 548 trial of nivolumab therapy as an adjunct to standard chemoradiotherapy in patients with newly diagnosed MGMT-methylated glioblastoma 190 , and the open-label phase III CheckMate 498 trial assessing the efficacy of nivolumab as an alternative to temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma 191 CAR T-cell therapy. Another immunotherapeutic concept involves adoptive transfer of genetically engineered chimeric antigen receptor (CAR) T cells, which have been modified to express binding domains with a high affinity for tumour antigens linked to intra cellular signalling domains that trigger T-cell activation, proliferation, and persistence, similarly to normal T-cell receptors 192 . Severe 'on-tumour' toxicity, attributable to cytokine release by activated CAR T cells, has been associated with this therapeutic approach, for example, in patients with haematological malignancies 193 ; however, 'on-target, off-tumour' crossreactivity can also result in severe organ-specific toxicity, such as neurological toxicity owing to targeting of neurons expressing melanoma-associated antigen A (MAGE-A) proteins by autologous anti-MAGE-A3 CAR T cells 194 . Nevertheless, this treatment paradigm holds promise for glioma therapy. For instance, treatment with CAR T cells directed at EGFRvIII 195 or podoplanin 196 reduced glioma growth in mouse models. Early clinical trials using CAR T cells targeting EGFRvIII (REF. 197) or HER2 (REF. 198) are ongoing in patients with glioblastoma. HER2 expression on cardiomyocytes warrants close monitoring of cardiac function in patients who receive HER2-targeting CAR T cells; however, cardiac failure was not observed in 19 patients with sarcoma who were treated with such cell therapy 199 .
Innovative clinical trial design The low incidence of various gliomas poses a challenge to patient recruitment, and thus the initiation of sufficiently powered clinical trials. Generally, the number of events, and thus the statistical power of oncology trials, can be increased by creating national and international networks that maximize patient recruitment, by minimizing trial durations, by inclusion of composite or continuous outcome measures, such as quality-of-life outcomes, and by minimizing 'noise' , thereby ensuring high-data quality 200 . Historical controls have also been used to reduce sample size in previous single-arm phase II trials in patients with glioma, but a series of phase III trials with a rationale built on data from such trials had negative results 128, 129, 164 , thus raising questions regarding the validity of this approach. Of note, the overall survival of patients with glioblastoma treated in the standard chemoradiotherapy control arms of clinical trials has improved substantially over the past decade, ranging from 14.6 months in the pivotal EORTC/NCIC trial 79 to approximately 17 months in contemporary phase III trials [3] [4] [5] 135 -probably owing to improved surgical techniques, more-aggressive treatment of recurrent disease, and better management of treatment-related complications. Importantly, these improvements in care can distort the outcome measures of single-arm trials in which the survival of contemporary cohorts is compared with that of historical cohorts 201 . Molecular stratification of gliomas exacerbates the challenges of patient accrual, but might increase the yield of a study by accurately selecting the 'right' patients for treatment with the 'right' molecularly targeted therapies. A constant increase in knowledge of the molecular mechanisms that drive gliomagenesis and the failure of previous trials of molecular targeted therapies for gliomas underscore the need for a step back towards hypothesis-generating phase II trial designs: only combination treatments that also counter the anticipated escape mechanisms will ultimately overcome treatment resistance. Two-step designs, such as adaptive and crossover trials including repeat biopsy sampling to enable the use of molecular diagnostics, have been advocated for this purpose in the setting of other rare cancers 200 ; however, such designs might be difficult to apply in glioma trials owing to the costs and risks associ ated with cranial surgery, and because clinical deterioration at tumour progression can preclude further trial participation in a substantial proportion of patients. Nevertheless, comparisons of molecular tumour profiles before and after therapy, as well as examination of tissue from 'responders' versus 'nonresponders' are important in generating hypotheses for the identification of combination treatments that overcome resistance, and might yield novel biomarkers for prediction of escape mechanisms in individual patients.
Classic one-size-fits-all trial designs, whereby randomization is based on histology alone, are outdated (FIG. 5a) , and biomarker-based entry criteria are increasingly being applied. Different treatment options can then be randomly allocated to biomarker-positive versus biomarker-negative patients, in order to maxi mize recruitment (FIG. 5b) . In trials involving patients with diffuse gliomas, IDH mutation, 1p/19q codeletion, and MGMT-promoter methylation are commonly determined at diagnosis and are candidates for biomarker-based stratification. Several ongoing trials are incorporating more-specific molecular entry criteria. For example, assessment of EGFR amplification is being performed in the clinical development programme of the anti-EGFR antibody-drug conjugate ABT-414 (REFS 202, 203) , and in an uncontrolled trial of the small-molecule EGFR-inhibitor dacomitinib 204 (which is anticipated to cross the blood-brain barrier more readily than previously evaluated EGFR inhibitors 92, 93 ). Moreover, assessment of rare fusion proteins and activating mutations involving the FGFR gene 95, 96 is being incorporated into a trial of a novel FGFR-inhibitor (BGJ398) 205 . Basket trials extend biomarker-based patient recruitment according to the rationale that a particular molecular alteration validates a clinical target for which a specific inhibitor is available, independent of disease site or histology. By contrast, umbrella trials offer the opportunity to maximize recruitment by enabling patient stratification using multiple molecular markers, for example, particular genetic alterations detected in subsets of patients with the same cancer type that can be targeted with different inhibitors (FIG. 5c) . In basket and umbrella trials, the intention is not to compare the outcomes of patients in the different treatment arms. Instead, these designs can be viewed as incorporating several separate phase II trials -enabling investigations of the efficacy of either a single agent in the various different diseases included in the 'basket' of a common molecular target, or multiple different therapies allocated based on molecular profiles under the 'umbrella' of a common disease. Randomization of patients with rare cancers to a control arm is not feasible and, therefore, response assessment is the primary outcome measure used in these trials. The possibility of prospective annotation of clinical and molecular data to generate hypotheses for testing in future randomized trials is a key strength of basket and umbrella trials; thus, repeated biopsy sampling at disease progression should be included in such designs.
Tremendous technological progress in micro arraybased and NGS-based diagnostics provides novel opportunities for such innovative trial approaches, although molecular stratification using high-throughput technologies is challenged by logistical issues, such as the availability of sufficient amounts of tissue, insufficient depths of sequencing to detect clones of low abundance, consumption of time and resources, and a limited consensus on data interpretation 206 . Moreover, basket and umbrella trials require a functional molecular screening platform and potentially the involvement of multiple pharmaceutical companies in order to obtain a reason able assortment of drugs with which to target the detected molecular aberrations, but are, nevertheless, the most-promising approach to developing a precisionmedicine strategy for patients with glioma. Ongoing or upcoming prospective studies using NGS-based diagnostics include the INFORM registry basket trial in paediatric patients with recurrent cancers including gliomas 97 , the N 2 M 2 umbrella trial in patients with newly diagnosed MGMT-promoter-unmethylated glioblastoma 98 , and the NCI-MATCH trial in adult patients with any type of advanced-stage cancer, including gliomas 99 .
Conclusions
Advances in molecular profiling technologies have enabled the characterization of genetic and epigenetic changes in gliomas at a hitherto unprecedented level of detail. New biomarkers have been identified that can improve the diagnostic accuracy and guide the use of individualized treatments. These developments have led to the 2016 update of the WHO Classification of Tumours of the CNS that breaks with the traditional approach of purely histology-based glioma diagnostics by incorporating molecular biomarkers into an integrated diagnosis. In parallel, improved knowledge of glioma biology has provided opportunities for novel pathogenesis-based pharmacological treatments and innovative immunotherapeutic strategies; for example, new strategies for targeting tumour-associated mutant proteins or immune checkpoints have emerged. Moreover, innovative trial concepts have been initiated that involve predictive molecular profiling followed by individualized therapy specifically tailored to the characteristics of each tumour. Thus, the time has come to expand the implementation of precision medicine in neuro-oncology.
